A Review of the SQ-109 Patent Landscape: A Scoping Report

SQ-109 falls into the class of drugs known as ethylenediamines. The compound was discovered by Sequella Inc in collaboration with the United States National Institutes of Health (NIH). A solid phase method was developed to synthesize more than 63 000 compounds based on the 1,2-ethylenediamine structure of ethambutol. Using a high-throughput screening assay, compounds were identified that affected genes activated during cell membrane repair by the TB bacilli.

Given the potential of SQ109, this report explores the patent landscape and considers possible access issues relating to the drug should it become available on the market.